Sort
82,697 grants matching “vaccine development”
Characteristics and protective efficacy of human antibodies against M. tuberculosis
$716,093Jacqueline Michele Achkar · Albert Einstein College Of Medicine · R01 · FY2023 · AI
DNA Vaccines
$716,083George N. Pavlakis · Basic Sciences · Z01 · FY2007 · CA
Defining the Inflammation and Immunity Transcriptome in Severe Malarial Anemia for Immunotherapeutic Discovery
$716,070Douglas Jay Perkins · University Of New Mexico Health Scis Ctr · R01 · FY2019 · AI
A Multidisciplinary Approach to Understanding TB Latency and Reactivation
$716,068Petros C Karakousis · Johns Hopkins University · R01 · FY2013 · HL
Impact of Early-life Exposure to Semi-Volatile Organic Compounds (SVOCs) on Neonatal and Early Childhood Immune Function
$716,067Jennifer K Hoffman · Duke University · R01 · FY2022 · AI
Chronic Wasting Disease Vaccines
$716,065Candace K. Mathiason · Colorado State University · R01 · FY2021 · AI
Mapping and modeling host-pathogen interactions in TB latency and reactivation
$716,036Maria Laura Gennaro · Univ Of Med/Dent Of Nj-Nj Medical School · R01 · FY2012 · HL
Biomarker Approach to Screening for the early detection of HPV-related Oropharyngeal Cancer (BASH OPC)
$715,985Anna R Giuliano · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2025 · DE
Intersubtype recombinants for polyvalent anti-HIV vaccine
$715,983Yong Gao · Case Western Reserve University · R01 · FY2011 · AI
DEVELOPMENT OF A LIPOSOMAL PNEUMOCOCCAL VACCINE FOR CLINICAL READINESS
$715,951Charles Houston Jones · Abcombi Biosciences, Inc. · R44 · FY2020 · AI
The Protective and Pathologic Features of the EVD Survivor Immune System
$715,921William Fischer · Univ Of North Carolina Chapel Hill · R01 · FY2023 · AI
HUMAN IMMUNE RESPONSES TO HPV VACCINES
$715,846Johns Hopkins University · P01 · FY2001 · AI
Analysis of immunity, viral adaptation and pathogenesis in a new mouse model of HCV-related rodent hepacivirus infection
$715,770Charles M. Rice · Rockefeller University · R01 · FY2018 · AI
Conformational Landscape of the HIV-1 Envelope Glycoproteins
$715,679Joseph G Sodroski · Dana-Farber Cancer Inst · R01 · FY2016 · AI
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment Following Hematopoietic Stem Cell Transplantation
$715,637Michael Daniel Keller · Children'S Research Institute · R01 · FY2023 · HL
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment Following Hematopoietic Stem Cell Transplantation
$715,637Michael Daniel Keller · Children'S Research Institute · R01 · FY2022 · HL
St. Jude/Memphis IMPAACT Clinical Trials Unit (Composite)
$715,557Patricia Michele Flynn · St. Jude Children'S Research Hospital · U01 · FY2010 · AI
Clinical trials employing cancer vaccine combination therapies
$715,531James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Interruption of maternal-fetal transmission of HIV
$715,530Joseph M McCune · University Of California, San Francisco · R01 · FY2012 · AI
Initial clinical evaluation of attenuated Shigella flexneri 2a live vector expressing enterotoxigenic Escherichia coli antigens, strain CVD 1208S-122.
$715,435Wilbur H. Chen · University Of Maryland Baltimore · U01 · FY2023 · AI
Genetic Analysis of Toxinogenesis in Vibrio Cholerae
$715,353John J Mekalanos · Harvard Medical School · R01 · FY2018 · AI
Genetic Analysis of Toxinogenesis in Vibrio Cholerae
$715,353John J Mekalanos · Harvard Medical School · R01 · FY2016 · AI
Genetic Analysis of Toxinogenesis in Vibrio Cholerae
$715,353John J Mekalanos · Harvard Medical School · R01 · FY2017 · AI
Genetic Analysis of Toxinogenesis in Vibrio Cholerae
$715,353John J Mekalanos · Harvard Medical School · R01 · FY2015 · AI
Genetic Analysis of Toxinogenesis in Vibrio Cholerae
$715,353John J Mekalanos · Harvard Medical School · R01 · FY2014 · AI